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Methods
We analysed a random sample of blinded randomized clinical trials indexed in the The Cochrane Central Register of Controlled Trials and published in 2001.
We identified 1599 blinded trials, and noted if they had conducted any test for the success of blinding. We also selected 200 trials randomly that did not report any such test, and sent a questionnaire to the corresponding authors asking them if they had conducted any tests.
Results
Thirty-one out of 1599 trials (2%) reported tests for the success of blinding. Test methods varied, and reporting was generally incomplete. Blinding was considered successful in 14 out of the 31 trials (45%) and unclear in 10 (32%).
Of the seven trials (23%) reporting unsuccessful blinding the risk of a biased trial result was either not addressed or was discounted in six cases. We received 130 questionnaires from trial authors (65%) of which 15 (12%) informed that they had conducted, but not published, tests.
Conclusions Blinding is rarely tested. Test methods vary, and the reporting of tests, and test results, is incomplete. There is a considerable methodological uncertainty how best to assess blinding, and an urgent need for improved methodology and improved reporting. 
Background
Blinding can reduce bias in randomized clinical trials. A metaanalysis of studies of bias found that trials described as 'double blind' in trial reports found 14% lower treatment effects, on average, than similar trials not described as 'double blind'. 1 Bias may occur due to inadequate blinding of several key trial persons. Blinded trial participants may report symptoms differently than unblinded ones, 2 or differ in their tendency to drop out of the trial, or seek non-protocolized treatment. Blinded health care providers may also differ from unblinded ones in their degree of attention to patients 3 or in their use of alternative forms of care. Similarly, blinded data collectors, 4, 5 end-point committees and data analysts may differ from unblinded ones in their handling of data. It is unclear how often key trial persons intended to be blind (e.g. patients, healthcare providers, data collectors, end-point committees or data analysts) are unblinded during a trial. Critical appraisal of the risk of unblinding is often difficult because the reporting of the blinding status of key trial persons, and of the blinding procedures, is frequently incomplete or missing, 6, 7 despite the CONSORT statement's suggestion to report these issues.
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Another possible way of assessing whether blinding has been successful is to ask key trial persons to guess patients' treatments and compare the answers with the actual treatments. Previous analyses of such trials indicated that unblinding could be common but were based on small samples of trials published in a few selected journals, [9] [10] [11] or were restricted to trials that had reported testing the success of blinding in the titles or abstracts. 11 Therefore, the results may not be generalizable.
Our objective was to assess how often randomized clinical trials test the success of blinding, which methods are used, and how often blinding is reported to be successful.
Methods
We )'. We identified 5079 references. We arbitrarily aimed at identifying at least 25 trials that tested the success of blinding. Based on computer-generated random numbers we initially selected 500 of the 5079 references, read the corresponding trial reports and assessed the likely number of trial reports needed. Secondarily, we randomly selected a further 1750 references, and retrieved the corresponding publications.
From this initial sample of 2250 references, we excluded 632 non-randomized or non-blinded trials, laboratory experiments, studies on healthy volunteers or health economics analyses, as well as 19 non-English articles that we could not read. The database thus consisted of 1599 blinded randomized clinical trials published in 2001.
All trial reports were read by one reviewer to identify trials that reported tests for blinding. To make sure we had not overlooked any eligible trials 400 randomly selected trials (25%) were read a second time by a different reviewer. No overlooked trials were found.
From the database of 1599 trials we defined two groups of trials. The first group consisted of all trials that reported tests of the success of blinding in the journal article. The second group consisted of 200 of the remaining trials that did not describe such tests, sampled by a computer-generated list of random numbers. No formal sample size calculation was made.
From both groups of trials, we extracted the design of the trial, the experimental and control interventions, indicators of trial quality (generation of allocation sequence, concealment of allocation, double blinding, intention-to-treat analysis, funding source and size of trial), 1, 12, 13 the clinical speciality involved, the key trial persons intended to be blinded, and the time of unblinding. Two authors independently extracted the data on pretested forms and any disagreements were solved by discussion. We considered a trial blinded if the trial report used the term 'blinded' (or similar, e.g. 'masked') to describe the intention of keeping at least one key trial person ignorant of the allocated treatment of patients. We pragmatically considered a trial as 'double blind' if described by that term in the trial report; and similarly we regarded the result as analysed by 'intention to treat' if the trial report used that term. We defined adequate generation of the allocation sequence as computer-generated random numbers, random numbers lists, flip of coin, drawing of cards or lots or comparable methods of stochastic generation. Adequate concealment of the allocation sequence was defined as: central randomization (including pharmacy controlled), numbered or coded vehicles, sealed or opaque envelopes or comparable methods of concealment.
From the first group of trials that published tests of the success of blinding we furthermore extracted the following data: the type of key trial persons tested, the number of tested persons, the response categories, the results, the use of any statistical test and the trial report conclusion. We classified the success of blinding according to the conclusion of the authors of the trial reports.
We sent an e-mail to the primary authors of the 200 trials in the second group that did not test the success of blinding. The e-mail provided a link to a web-based questionnaire. To those without an identifiable e-mail address we posted a printed version. We asked the authors whether they had formally tested the success of blinding, despite not having reported such a test. If a test had been conducted we subsequently asked the author how the test was performed and what the result was. Reminders were sent out after 2, 4 and 6 weeks. The questionnaire included additional items on blinding of key trial persons. Results based on these questions is reported elsewhere. 7 Proportions were compared using Fisher's exact test, and medians using Mann-Whitney's test. P-values are two-sided.
Results
Thirty-one out of the 1599 trial publications (2%; 95% confidence intervals: 1.3 to 2.7%) reported tests for the success of blinding (Table 1 , Appendix, ).
Trials that publish tests for the success of blinding (n ¼ 31)
Blinding was concluded successful in 14 of the 31 trials (45%; 27 to 64%), unsuccessful in seven trials (23%; 10 to 41%), whereas 10 trials (32%; 17 to 51%) had unclear or no conclusions. The majority of trials was of parallel group design, investigated a drug and used a placebo control (Table 1) . Twenty-five trials (81%) were described as 'double blind', 11 (35%) had adequate concealment of allocation and six (19%) conducted intention-to-treat analyses. The four most frequent medical specialties or research areas represented were psychiatry, public health, anaesthesiology and complementary alternative medicine ( Table 1 ). The median number of included patients per trial was 56 (interquartile range . The median number of persons tested for the success of blinding per trial was 40 (interquartile range 20-64).
The trial reports described explicitly the blinding of patients in 26 trials (84%), and the blinding of data collectors in nine trials (29%) ( Table 2 and Appendix). Four of these trials described the blinding of both patients and data collectors. In 15 trials (48%) one or more key trial person, explicitly described as blinded in the trial report, was not tested for the loss of blinding. The primary outcome was patient reported (e.g. pain) in 14 trials (45%), and observer reported (e.g. assessment of sedation success) in 17 trials (55%) ( Table 2 and Appendix). Patients' cooperation was involved in 15 of the 17 trials with observer reported outcomes (e.g. raters scoring potentially depressed patients on Hamilton Rating Scale for Depression).
The methods used to test the success of blinding varied considerably. Most trials tested only the blinding of patients and asked them to guess between experimental or control treatment, without the option of a 'don't know' category (Table 3) . Twenty-three trials tested patients only (74%). Four trials tested data collectors only (13%), three trials both patients and data collectors (10%) and one trial healthcare providers and data collectors (3%).
In 30 trials (97%) the types of key trial persons who were tested were directly involved in the reporting of the primary outcome. In 14 of these 30 trials patients were tested in trials with patient reported outcomes. In 15 other trials with observer reported outcomes that involved patients' cooperation, either patients or data collectors were tested. Only in two such trials were both patients and data collectors tested (Appendix and Table 2 ). Twenty-eight trials (90%) tested persons only at the end of treatment whereas three trials (10%) also tested at various times during the trial. Three trials (10%) rated the confidence of tested persons in their guesses or asked for reasons for guesses. No trials tested whether the experimental and control treatments appeared identical before the proper trial started by e.g. asking volunteers to identify any variation in colour, taste and texture.
The results were analysed with Chi-square or Fisher's exact tests in eight trials (26%), and three trials (10%) used other tests (Table 3) . One trial (3%) used the test as a measure for effect and not an indication for possible bias as it assumed that blinding could only be compromised by the effect of treatment. 43 The reporting was generally incomplete. Ten trial reports (32%) contained no clear conclusion concerning the result of the test. In 24 trials (77%) it was impossible to reconstruct a table that related key trial persons' treatment guesses to actual treatment allocation. In most cases only the proportion of correct, or incorrect, guesses was reported. In 18 trials (58%) no statistical analysis was presented, and in an additional two trials (6%) the result of the analysis was unclear ( Table 3) .
The seven trials with tests that indicated unsuccessful blinding differed in their way of handling this information. One trial report emphasized the risk of bias when discussing its result. 44 A second report emphasized that loss of blinding did not necessarily imply bias. 19 Five other trial reports made no clear statement concerning the risk of bias, 29, 34, 36, 37, 43 but interpreted the loss of blinding as caused by an effect of the treatment, 29, 34, 37 by lack of effect in the placebo group, 36 or by side effects to the treatment. 43 Four of the seven trials with unsuccessful blinding concluded that the experimental treatment had an effect on at least one outcome without discussing the possibility of bias. 29, 34, 36, 37 Thus, in six out of seven cases the risk of bias was either not addressed or was discounted.
Trials that did not publish tests for the success of blinding (n ¼ 200)
The majority of trials were of parallel group design, investigated a drug and used a placebo control (Table 1 ). There were 156 (78%) trials described as 'double blind', 37 (19%) had adequate concealment of allocation and 57 (29%) conducted intention-to-treat analyses. The median number of patients was 58 (interquartile range 30-149). The four most frequent clinical specialties represented were anaesthesiology, psychiatry, cardiology and allergology/pulmonology (Table 1) . We received 130 of the 200 questionnaires (response rate 65%). Of the 130 trial report authors, 15 (12%) responded that they had formally tested the success of blinding without reporting this in the journal article (Table 4) . Eleven of these 15 responders (73%) reported success of blinding, two (13%) reported 'partial loss of blinding', and two did not report the result (13%). Nine of the 15 trial authors (60%) informed that the data on the success of blinding had been assessed without a formal statistical test.
Trials that publish tests vs other trials
Among the trials that published tests for the success of blinding there was a higher proportion of psychiatry and public health trials compared with the other trials ( Table 1 ). There were no marked differences with respect to other trial characteristics or indicators of methodological quality (Table 1 ). These findings were not sensitive to the exclusion of 15 trials with unpublished tests (data not shown). Thus, there was no clear tendency for trials that test the success of blinding to be of marked higher methodological quality than trials in general.
Discussion
Few trialists published tests of the success of blinding. There was considerable variation in how tests were conducted, and a high prevalence of incompletely, and unreported, tests. Less than half of the trial reports concluded that blinding had been successful.
Strength and weaknesses of the study
Our study is based on a large, recent and representative sample of trials across a broad range of study designs, specialities and journals. We identified a moderately sized group of trials that reported a test of blinding. Furthermore, we studied the proportion of unreported tests by contacting authors of trial reports that did not describe tests of blinding. However, the reporting on tests was often incomplete. Roughly three out of four trials did not report full data for a table relating test persons' guesses to actual treatment. Furthermore, one of eight trial authors declared unpublished tests in their questionnaire. The decision whether to publish the result, and with what degree of detail, involve considerable subjectivity. There is a strong incentive for successful blinding, as this strengthens the validity of the trial. Possible selective reporting 49 could have resulted in underreporting of unsuccessful blinding. Thus, our review reflects the results of published tests, but not necessarily that of conducted tests.
Comparison with other studies
Fergusson and colleagues analysed 191 placebo-controlled trials published in top journals. 10 They identified 15 trials (8%) that tested the success of blinding, of which nine trials (60%) reported unsuccessful blinding. Boutron and colleagues analysed 127 trial reports in top journals, and searched medical data bases for trial reports that mentioned tests in the title or abstract. 11 They identified 13 trials that tested blinding published in top journals (8%), and 82 in total. Of the 54 trials assessing the success of blinding of patients, 22 trials (41%) reported unsuccessful blinding.
However, results from these studies may not be generalizable because a small sample of placebo-controlled trials could differ from trials in general. Furthermore, authors that describe a test in the title or abstract may do so partly depending on the result of the test. Thus, our study adds considerably improved generalizability, because we sampled randomized clinical trials directly from a database, and comprehensiveness because the number of included trials is larger, and because we also analysed a group of trials that did not report tests.
Methodological uncertainty of how best to evaluate the success of blinding
Both inadequate randomization and blinding is associated with bias.
1 Randomization is often evaluated by comparing the baseline characteristics of patients. 45 Blinding can be evaluated by an informal assessment of the reported blinding practices, but this approach is subjective, and highly dependent on adequate reporting of the blinding procedures, which is very uncommon.
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The alternative approach is to assess the success of blinding with a formal test. However, there is no methodological consensus of whether such tests are appropriate, and if so, how, and at what time, they should be conducted. 10, 46 A positive test conducted during, or after the end of, the trial, cannot be interpreted as clear indication of bias, as unblinding may be caused by a true effect, and lack of blinding may not cause bias (e.g. if the outcome is mortality). Sackett suggests conducting a test on volunteers before the proper trial starts, 46 but this procedure does not evaluate whether blinding was maintained during the trial. There is also uncertainty of the best way to ask patients, e.g. whether questions should include a do not know category. Furthermore, the statistical problems of how to analyse data from such tests have only recently been analysed, and the suggested solutions need further validation. 47, 48, 50, 51 This methodological uncertainty is reflected in our findings. Most trials tested only one out of several intended blinded key trial persons. The selection criteria for who to test was often unclear, e.g. patients, and not data collectors, were tested in 10 trials with observer reported primary outcomes. Roughly half of the trials did not include a 'don't know' option when testing, and few trials had follow up questions that could elucidate reasons for guesses. The statistical analyses were in many cases unclear, and in some cases absent. Furthermore, six out of seven trial reports describing a test that indicated loss of blinding either disregarded, or ignored, the risk of bias due to unblinding. All in all, in many trials that test the success of blinding these problems preclude a definite conclusion on the blinding status of key trial persons.
Implications
In most trials critical appraisal of the success of blinding is not meaningful because of grossly incomplete reporting of both the blinding procedures, 6, 7 and any test for the success of blinding, and because of the methodological uncertainty concerning such tests. In conclusion, we found that tests for the success of blinding are rarely performed. When they are performed, there is considerable variation in the methods of testing and analysis, and a high proportion of incompletely reported and unreported tests. There is an urgent need for improving the methods of evaluating the success of blinding. The success of blinding is rarely tested e.g. by asking key trial participants to guess patients' treatments.
The test methods vary; and the reporting of tests, and test results, is incomplete.
Seven of 31 trials (23%) reported tests indicating loss of blinding, but in six of the seven cases the risk of a biased trial result was disregarded.
There is considerable methodological uncertainty about how to assess blinding, and an urgent need for improved methodology and improved reporting. 
